statistiche ricercatore

Continente	#
NA - Nord America	507
AS - Asia	352
EU - Europa	336
SA - Sud America	73
AF - Africa	16
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.286

Nazione	#
US - Stati Uniti d'America	487
SG - Singapore	172
IT - Italia	76
CN - Cina	70
SE - Svezia	64
BR - Brasile	59
FR - Francia	48
DE - Germania	35
VN - Vietnam	30
IE - Irlanda	24
FI - Finlandia	23
GB - Regno Unito	16
IN - India	15
CA - Canada	14
ID - Indonesia	13
PL - Polonia	10
AT - Austria	8
ES - Italia	8
HK - Hong Kong	8
JP - Giappone	8
RU - Federazione Russa	8
AR - Argentina	7
BD - Bangladesh	7
ZA - Sudafrica	7
PK - Pakistan	6
TR - Turchia	6
CI - Costa d'Avorio	4
MA - Marocco	4
UZ - Uzbekistan	4
CO - Colombia	3
IR - Iran	3
VE - Venezuela	3
BE - Belgio	2
IQ - Iraq	2
KZ - Kazakistan	2
MX - Messico	2
NL - Olanda	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AU - Australia	1
AZ - Azerbaigian	1
BY - Bielorussia	1
CH - Svizzera	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
GL - Groenlandia	1
GR - Grecia	1
GT - Guatemala	1
IL - Israele	1
IM - Isola di Man	1
JM - Giamaica	1
JO - Giordania	1
KE - Kenya	1
LT - Lituania	1
MD - Moldavia	1
OM - Oman	1
PA - Panama	1
PE - Perù	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
TW - Taiwan	1
UA - Ucraina	1
Totale	1.286

Nome	#
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition	157
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice	147
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV	145
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition	136
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice	120
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice	117
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study	112
People Living with HIV in the COVID-19 Era: A Case Report	97
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV	95
Evaluation of doravirine-based regimen population target in a large Italian clinical center	94
Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al	89
Totale	1.309

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	15	0	0	0	0	0	0	0	0	0	10	2	3
2021/2022	75	2	1	0	5	0	1	5	9	2	2	7	41
2022/2023	297	33	41	14	48	10	34	12	40	38	2	21	4
2023/2024	143	4	27	1	10	4	21	15	4	10	12	18	17
2024/2025	254	3	3	51	11	14	15	15	7	35	23	36	41
2025/2026	501	88	9	28	58	109	25	75	27	57	25	0	0
Totale													1.309

IRIS UniCatt